COVID-19 and Tuberculosis: Two Knives in a Sheath
Authors:
- Bupesh GiridharanBGBupesh Giridharan
- Konda Mani SaravananKonda Mani Saravanan
- Kishore Kumar Meenakshi SundaramKSKishore Kumar Meenakshi Sundaram
- Attuluri Vamsi KumarAKAttuluri Vamsi Kumar
- Sangeetha RajendranSRSangeetha Rajendran
- AlemtoshiALAlemtoshi
- Vellingiri BalachandarVBVellingiri Balachandar
- Pranjal BharaliPBPranjal Bharali
- 1 October 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Coronaviruses
- Vol. 3 (5) , 1
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has caused a global human outbreak, making it a more serious threat to human health than any other infectious disease. Coronavirus infectious disease 2019 (COVID-19) has severely affected the lifestyles of people around the world and caused high mortality throughout the world. In both pandemic and seasonal influenza, co-infection of COVID-19 with other diseases has been linked to worse outcomes. The literature revealed that it is characteristically associated with comorbidities such as hypertension, blood pressure, obesity, cardiovascular diseases, and other microbial infections. Furthermore, microbial coinfections worsen respiratory viral infections and are a common cause of death in influenza pandemics. Deplorably, Tuberculosis (TB) is also a dreadful lung infection and attains cytokine equilibrium with host cells to maintain the latent stage. Studies showed that human coronaviruses (hCoV) activate latent TB to an active state due to unregulated cytokine production, called a cytokine storm. The present review concisely discusses the reason and status of co-infection of COVID-19 with TB based on previous case reports, cohorts, and scientific studies. COVID-19 patients are prone to be infected with TB and vice-versa in TB-prone areas. The therapeutic opportunities for overcoming the COVID-19 induced cytokine storm have also been emphasized by the present clinical trial candidates. In conclusion, we recommend categorizing the patients based on their medical history and cured or latent TB patients should be particularly closely monitored. They should be tested for Interferon Gamma Release Assay (IGRA) regularly on and after COVID-19 infection.Keywords
This publication has 118 references indexed in Scilit:
- CCL2/MCP-I Genotype-Phenotype Relationship in Latent Tuberculosis InfectionPLOS ONE, 2011
- A Role for the Chemokine RANTES in Regulating CD8 T Cell Responses during Chronic Viral InfectionPLOS Pathogens, 2011
- Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+T Cells Are Important in Control of SARS-CoV InfectionJournal of Virology, 2010
- Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Management of individuals requiring antiretroviral therapy and TB treatmentCurrent Opinion in HIV and AIDS, 2010
- T cells in mycobacterial infection and diseaseCurrent Opinion in Immunology, 2009
- Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic CellsJournal of Virology, 2009
- The association of RANTES polymorphism with severe acute respiratory syndrome in Hong Kong and Beijing ChineseBMC Infectious Diseases, 2007
- Severe Acute Respiratory Syndrome and Pulmonary TuberculosisClinical Infectious Diseases, 2004
- Respiratory infections: SARS and tuberculosisClinics in Occupational and Environmental Medicine, 2004